24 results
Thumbnail

D1.74 - Molecular IgE sensitization profiling in a patient with Asteraceae weed pollen allergy and anaphylaxis to honey

Thumbnail

D1.75 - Anaphylaxis during Picc Line replacement

Thumbnail

D1.76 - The Hot Chocolate Drink Dilemma

Thumbnail

D1.77 - Perioperative Hypersensitivity Outcomes: A retrospective review of 112 patients seen between 2019 and 2024 at two allergy centres

Thumbnail

D1.78 - Analytical Verification of Omega-5 gliadin (Tri a 19) Allergen Assay on the IMMULITE 2000 XPi System*

Thumbnail

D1.79 - Cardiovascular symptoms during anaphylaxis: An analysis from the European Anaphylaxis Registry

Thumbnail

D1.82 - Diagnostic challenges in amoxicillin-clavulanate anaphylaxis: an inconclusive in vitro study – Case Report

Thumbnail

D1.83 - Asthma and multi-food allergy were risk factors for Oral Food Challenge failure

Thumbnail

D1.84 - IgE-mediated allergy to chlorhexidine: case report

Thumbnail

D1.85 - Basophil activation test in β-Lactam Anaphylaxis: A Case Series from a Tertiary Hospital

Thumbnail

D1.86 - Hypersensitivity Reaction to Lugol’s Solution: A Case Report

Thumbnail

D3.178 - Efficacy of Index of reactivity (IR) liquid sublingual immunotherapy in allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies

Thumbnail

D3.179 - Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience

Thumbnail

D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme

Thumbnail

D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden

Thumbnail

D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy

Thumbnail

D3.184 - Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study

Thumbnail

D3.185 - The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting

Thumbnail

D3.186 - A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase

Thumbnail

D3.187 - Adverse reactions to sublingual immunotherapy with carbamylated allergoids of different sources in clinical studies